Adjuvants for vaccines to drugs of abuse and addiction

Vaccine

Volumn 32, Issue 42, 2014, Pages 5382-5389

  Alving, Carl R ^a   Matyas, Gary R ^a   Torres, Oscar ^a,b   Jalah, Rashmi ^a,b   Beck, Zoltan ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Adjuvants; Cocaine; Heroin; Hydrocodone; Immunotherapeutic vaccines; Methamphetamine; Morphine; Nicotine; Oxycodone

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; COCAINE; DIAMORPHINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; LIPOSOME; METHAMPHETAMINE; NICOTINE; OXYCODONE; PHOSPHORYL LIPID A; VACCINE; ALUMINUM DERIVATIVE; EMULSION; HAPTEN; INCOMPLETE FREUND'S ADJUVANT; LIPID; LIPID A;

ADSORPTION; DRUG ABUSE; DRUG DEPENDENCE; EMULSION; HAPTEN CARRIER COMPLEX; HEROIN DEPENDENCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; METHAMPHETAMINE DEPENDENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOBACCO DEPENDENCE; ANALOGS AND DERIVATIVES; IMMUNOLOGY; PHARMACOLOGY; SUBSTANCE-RELATED DISORDERS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; EMULSIONS; FREUND'S ADJUVANT; HAPTENS; HUMANS; LIPID A; LIPIDS; LIPOSOMES; SUBSTANCE-RELATED DISORDERS; VACCINES;

EID: 84922398714     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.085     Document Type: Review

References (105)

1. Degenhardt L., Whiteford H.A., Ferrari A.J., Baxter A.J., Charlson F.J., Hall W.D., et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382(November (9904)):1564-1574.
2. Evans J.L., Tsui J.I., Hahn J.A., Davidson P.J., Lum P.J., Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol 2012, 175(February (4)):302-308.
3. Sosa-Estáni S., Rossi D., Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: high seroprevalence of HIV infection. Clin Infect Dis 2003, 5(December (37 Suppl)):S338-S342.
4. UNODC World Drug Report (United Nations publication, Sales No. E.12.XI.1) 2012.
5. Kosten T.R., Domingo C.B. Can you vaccinate against substance abuse?. Expert Opin Biol Ther 2013, 13(August (8)):1093-1097.
6. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Gardner T., Kosten T.R. The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep 2007, 9(October (5)):381-387.
7. Kinsey B.M., Jackson D.C., Orson F.M. Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 2009, 87(May-June (4)):309-314.
8. Janda K.D., Treweek J.B. Vaccines targeting drugs of abuse: is the glass half-empty or half-full?. Nat Rev Immunol 2012, 12(1):67-72.
9. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin Pharmacol Ther 2012, 91(January (1)):60-70.
10. The Specificity of Serological Reactions, revised 1945, Dover, New York. K. Landsteiner (Ed.).
11. Turner M. Antibodies. Immunology 2011, 65-85. Mosby, Edinburgh. 6th edition. I. Roitt, J. Brostoff, D. Male (Eds.).
12. Berzofsky J.A., Berkower I.A. Immunogenicity and antigen structure. Fundamental immunology 2013, 539-582. Lippincott Williams & Wilkins, Philadelphia. 7th edition. W.E. Paul (Ed.).
13. Van Vunakis H., Bradvica H., Benda P., Levine L. Production and specificity of antibodies directed toward 3,4,5-trimethoxyphenylethylamine, 3,4-dimethoxyphenylethylamine and 2,5-dimethoxy-4-methylamphetamine. Biochem Pharmacol 1969, 18(February (2)):393-404.
14. Spector S., Parker C.W. Morphine: radioimmunoassay. Science 1970, 168(June (3937)):1347-1348.
15. Spector S. Quantitative determination of morphine in serum by radioimmunoassay. J Pharmacol Exp Ther 1971, 178(August (2)):253-258.
16. Van Vunakis H., Farrow J.T., Gjika H.B., Levine L. Specificity of the antibody receptor site to d-lysergamide: model of a physiological receptor for lysergic acid diethylamide. Proc Natl Acad Sci U S A 1971, 68(July (7)):1483-1487.
17. Van Vunakis H., Wasserman E., Levine L. Specificities of antibodies to morphine. J Pharmacol Exp Ther 1972, 180(February (2)):514-521.
18. Leute R.K., Ullman E.F., Goldstein A., Herzenberg L.A. Spin immunoassay technique for determination of morphine. Nat New Biol 1972, 236(March (64)):93-94.
19. Langone J.J., Gjika H.B., Van Vunakis H. Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine. Biochemistry 1973, November (12)(24):5025-5030.
20. Mulé S.J., Bastos M.L., Jukofsky D. Evaluation of immunoassay methods for detection, in urine, of drugs subject to abuse. Clin Chem 1974, 20(February (2)):243-248.
21. Chase M.W. Preparation of immunogens. Methods in immunology and immunochemistry 1967, vol. I:197-209. Academic Press, New York.
22. Moncada C., Torres V., Israel Y. Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods 1993, 162(June (1)):133-140.
23. Butler V.P. The immunological assay of drugs. Pharmacol Rev 1977, 29(June (2)):103-184.
24. Zhang H., Wang S., Fang G. Applications and recent developments of multianalyte simultaneous analysis by enzyme-linked immunosorbent assays. J Immunol Methods 2011, 368(1-2):1-23.
25. Bonese K.F., Wainer B.H., Fitch F.W., Rothberg R.M., Schuster C.R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974, 252(December (5485)):708-710.
26. Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 2(April (24 Suppl)):S2-S44.
27. Baba T., Sato-Matsushita M., Kanamoto A., Itoh A., Oyaizu N., Inoue Y., et al. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med 2010, 8. 10.1186/1479-5876-8-84.
28. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 3(May (20 Suppl)):S56-S64.
29. Brunner R., Jensen-Jarolim E., Pali-Schöll I. The ABC of clinical and experimental adjuvants--a brief overview. Immunol Lett 2010, 128(January (1)):29-35.
30. Pentel P.R., Lesage M.G. New directions in nicotine vaccine design and use. Adv Pharmacol 2014, 69:553-580.
31. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35(July (7)):2031-2040.
32. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89(March (3)):392-399.
33. Rüedi-Bettschen D., Wood S.L., Gunnell M.G., West C.M., Pidaparthi R.R., Carroll F.I., et al. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 2013, 31(September (41)):4596-4602.
34. Cerny E.H., Lévy R., Mauel J., Mpandi M., Mutter M., Henzelin-Nkubana C., et al. Preclinical development of a vaccine 'against smoking'. Onkologie 2002, 25(October (5)):406-411.
35. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20(January (7-8)):1196-1204.
36. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008, 3(June (6)):e2547. 10.1371/journal.pone.0002547.
37. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009, 66(October (10)):1116-1123.
38. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010, 67(January (1)):59-65.
39. Farhangi A., Akbarzadeh A., Mehrabi M.R., Chiani M., Saffari Z., Ghassemi S., et al. Safety of human therapeutic morphine vaccine employing Lohmann specific pathogen free eggs. Pak J Biol Sci 2010, 13(November (21)):1047-1051.
40. McCluskie M.J., Pryde D.C., Gervais D.P., Stead D.R., Zhang N., Benoit M., et al. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 2013, 16(May (1)):50-56.
41. Byrnes-Blake K.A., Carroll F.I., Abraham P., Owens S.M. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 2001, 1(February (2)):329-338.
42. Kosten T.A., Shen X.Y., O'Malley P.W., Kinsey B.M., Lykissa E.D., Orson F.M., et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45(August):223-229.
43. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24(April (16)):3232-3240.
44. Stowe G.N., Vendruscolo L.F., Edwards S., Schlosburg J.E., Misra K.K., Schulteis G., et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem 2011, 54(July (14)):5195-5204.
45. Schlosburg J.E., Vendruscolo L.F., Bremer P.T., Lockner J.W., Wade C.L., Nunes A.A., et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A 2013, 110(May (22)):9036-9041.
46. Bremer P.T., Janda K.D. Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem 2012, 55(December (23)):10776-10780.
47. Bremer P.T., Schlosburg J.E., Lively J.M., Janda K.D. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. Mol Pharmaceutics 2014, (in press).
48. Pravetoni M., Le Naour M., Tucker A.M., Harmon T.M., Hawley T.M., Portoghese P.S., et al. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 2013, 56(February (3)):915-923.
49. Pravetoni M., Raleigh M.D., Le Naour M., Tucker A.M., Harmon T.M., Jones J.M., et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012, 30(June (31)):4617-4624.
50. Taylor J.J., Laudenbach M., Tucker A.M., Jenkins M.K., Pravetoni M. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods 2014, 405(March):74-86.
51. Moreno A.Y., Azar M.R., Warren N.A., Dickerson T.J., Koob G.F., Janda K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm 2010, 7(April (2)):431-441.
52. Carrera M.R., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378(December (6558)):727-730.
53. Cai X., Tsuchikama K., Janda K.D. Modulating cocaine vaccine potency through hapten fluorination. J Am Chem Soc 2013, 135(February (8)):2971-2974.
54. Moreno A.Y., Mayorov A.V., Janda K.D. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc 2011, 133(May (17)):6587-6595.
55. Miller M.L., Moreno A.Y., Aarde S.M., Creehan K.M., Vandewater S.A., Vaillancourt B.D., et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 2013, 73(April (8)):721-728.
56. Lockner J.W., Ho S.O., McCague K.C., Chiang S.M., Do T.Q., Fujii G., et al. Enhancing nicotine vaccine immunogenicity with liposomes. Bioorg Med Chem Lett 2013, 23(February (4)):975-978.
57. Collins K.C., Janda K.D. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse. Bioconjug Chem. 2014, 25(March (3)):593-600.
58. Spector S., Berkowitz B., Flynn E.J., Peskar B. Antibodies to morphine, barbiturates, and serotonin. Pharmacol Rev 1973, 25(2):281-291.
59. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., Botka A.J., et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996, 2(October (10)):1129-1132.
60. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000, 22(October (10)):809-819.
61. Pravetoni M., Keyler D.E., Raleigh M.D., Harris A.C., Lesage M.G., Mattson C.K., et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol 2011, 81(May (9)):1164-1170.
62. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008, 8(November (11)):1589-1594.
63. Li Q.Q., Luo Y.X., Sun C.Y., Xue Y.X., Zhu W.L., Shi H.S., et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 2011, 119(December (6)):1271-1281.
64. Matyas G.R., Mayorov A.V., Rice K.C., Jacobson A.E., Cheng K., Iyer M.R., et al. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 2013, 31(June (26)):2804-2810.
65. Matyas G.R., Rice K.C., Cheng K., Li F., Antoline J.F., Iyer M.R., et al. Facial recognition of heroin vaccine opiates: Type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. Vaccine 2014, 32:1473-1479.
66. Sanderson S.D., Cheruku S.R., Padmanilayam M.P., Vennerstrom J.L., Thiele G.M., Palmatier M.I., et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 2003, 3(January (1)):137-146.
67. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf, accessed 11 July 2014.
68. Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther 2013, 13(January (1)):11-33.
69. Avci F.Y., Li X., Tsuji M., Kasper D.L. Carbohydrates and T cells: a sweet twosome. Semin Immunol 2013, 25(April (2)):146-151.
70. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(July (7)):505-517.
71. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(October (4)):492-503.
72. Alving C.R., Peachman K.K., Rao M., Reed S.G. Adjuvants for human vaccines. Curr Opin Immunol 2012, 24(June (3)):310-315.
73. Wassef N.M., Alving C.R., Richards R.L. Liposomes as carriers for vaccines. Immunomethods 1994, 4(June (3)):217-222.
74. Alving C.R., Rao M., Steers N.J., Matyas G.R., Mayorov A.V. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 2012, 11(June (6)):733-744.
75. Muderhwa J.M., Matyas G.R., Spitler L.E., Alving C.R. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci 1999, 88(December (12)):1332-1339.
76. Matyas G.R., Muderhwa J.M., Alving C.R. Oil-in-water liposomal emulsions for vaccine delivery. Methods Enzymol 2003, 373:34-50.
77. Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G., Vedvick T.S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 2011, 29(November (51)):9563-9572.
78. Becher E. Emulsions: Theory and Practice 1965, Reinhold, New York, [There is also a 3rd ed. New York: Oxford University Press; 2001]. 2nd ed. ACS Monograph No. 162.
79. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(June (3)):411-416.
80. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines--US perspective. Vaccine 2002, 20(May (Suppl 3)):S18-S23.
81. Felnerova D., Viret J.F., Glück R., Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004, 15(6):518-529.
82. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013, 12(January (1)):13-30.
83. Marciani D.J. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today 2014, 19(July (7)):912-920.
84. Sablan B.P., Kim D.J., Barzaga N.G., Chow W.C., Cho M., Ahn S.H., et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30(March (16)):2689-2696.
85. Eng NF1, Bhardwaj N., Mulligan R., Diaz-Mitoma F. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother 2013, 9(August (8)):1661-1672.
86. Dynavax hepatitis B vaccine information. , accessed 12.07.14. http://www.dynavax.com/hepatitis_bv.html.
87. Muderhwa J.M., Rothwell S.W., Alving C.R. Emulsification of liposomes with incomplete Freund's adjuvant: stability of the liposomes and the emulsion. J Liposome Res 1998, 8:183-194.
88. Pierce M.A., Ellis R.D., Martin L.B., Malkin E., Tierney E., Miura K., et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 2010, 28(March (10)):2236-2242.
89. Woodard L.F. Surface chemistry and classification of vaccine adjuvants and vehicles. Adv Biotechnol Processes 1990, 13:281-306.
90. Rudbach J.A., Johnson D.A., Ulrich J.T. Ribi adjuvants: chemistry biology and utility in vaccines for human and veterinary medicine. The theory and practical application of adjuvants 1995, 287-313. John Wiley & Sons, New York. D.E.S. Stewart-Tull (Ed.).
91. Sigma Adjuvant System Product Information. accessed on 9.04.14. https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Datasheet/5/s6322dat.pdf.
92. Lipman N.S., Trudel L.J., Murphy J.C., Sahali Y. Comparison of immune response potentiation and in vivo inflammatory effects of Freund's and RIBI adjuvants in mice. Lab Anim Sci 1992, 42(April (2)):193-197.
93. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Shneerson J., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346(February):f794.
94. Hem S.L., HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6(October (5)):685-698.
95. Hem S.L., Johnston C.T., HogenEsch H. Imject® Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007, 25(June (27)):4985-4986.
96. HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2013, 3(January):406. 10.3389/fimmu.2012.00406.
97. Vecchi S., Bufali S., Skibinski D.A., O'Hagan D.T., Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J Pharm Sci 2012, 101(January (1)):17-20.
98. Weissburg R.P., Berman P.W., Cleland J.L., Eastman D., Farina F., Frie S., et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res 1995, 12(October (10)):1439-1446.
99. Alving C.R., Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 2008, 26(June (24)):3036-3045.
100. Kagan J.C. Immunology. Sensing endotoxins from within. Science 2013, 341(September (6151)):1184-1185.
101. Kayagaki N., Wong M.T., Stowe I.B., Ramani S.R., Gonzalez L.C., Akashi-Takamura S., et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013, 341(September (6151)):1246-1249.
102. Hagar J.A., Powell D.A., Aachoui Y., Ernst R.K., Miao E.A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013, 341(September (6151)):1250-1253.
103. Yokochi T., Inoue Y., Yokoo J., Kimura Y., Kato N. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect Immun 1989, 57(June (6)):1786-1791.
104. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 1992, 89(January (1)):358-362.
105. Fahim R.E., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines 2013, 12(March (3)):333-342.